{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:08:00Z","timestamp":1791673680188,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd014574","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000}}],"reference-count":83,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014574.pub2","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:11:42Z","timestamp":1751526702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rituximab for myasthenia gravis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Katherine C","family":"Dodd","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"Manchester Academic Health Science Centre; The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona J","family":"Clay","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine; Monash University; Southbank Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Forbes","sequence":"additional","affiliation":[{"name":"University of Tasmania; Hobart Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Handley","sequence":"additional","affiliation":[{"name":"University Hospitals Plymouth NHS Trust; Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Yann Shern","family":"Keh","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"National Hospital for Neurology and Neurosurgery; University College London Hospitals NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James AL","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Victoria Infirmary; Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Storms","sequence":"additional","affiliation":[{"name":"Library & Knowledge Service; Northern Care Alliance NHS Foundation Trust; Oldham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M","family":"White","sequence":"additional","affiliation":[{"name":"Lancaster Medical School; Lancaster University; Lancaster UK"},{"name":"Lancashire Centre for Clinical Neurosciences; Royal Preston Hospital; Preston UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Lilleker","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"Manchester Academic Health Science Centre; The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford UK"},{"name":"Manchester Academic Health Science Centre; The University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"10.1002\/14651858.CD014574.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1749-6632.1971.tb30741.x","article-title":"Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome","volume":"183","author":"Engel","year":"1971","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","article-title":"Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England","volume":"65","author":"Robertson","year":"1998","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD014574.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/wnl.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes Is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1002\/14651858.CD014574.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nature Reviews. Immunology"},{"issue":"11","key":"10.1002\/14651858.CD014574.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4049\/jimmunol.0901618","article-title":"Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity","volume":"184","author":"Stacy","year":"2010","journal-title":"Journal of Immunology"},{"issue":"1-2","key":"10.1002\/14651858.CD014574.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000500268","article-title":"A prospective study of the incidence of myasthenia gravis in the East Midlands of England","volume":"53","author":"Maddison","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1002\/14651858.CD014574.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Practical Neurology"},{"issue":"6","key":"10.1002\/14651858.CD014574.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0011|cit11","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale Journal of Biology and Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mus.26507","article-title":"Refractory myasthenia gravis: characteristics of a Portuguese cohort","volume":"60","author":"Santos","year":"2019","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurology"},{"issue":"8B","key":"10.1002\/14651858.CD014574.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1111\/j.1582-4934.2008.00431.x","article-title":"Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact","volume":"13","author":"Zamecnik","year":"2009","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014574.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/wnl.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Graham S MacLachlan S Exuzides A Buus R Harris L Jacob S PMS76 - Healthcare resource utilisation associated with refractory myasthenia gravis (MG), in comparison to non-refractory MG patients in England: a retrospective cohort study Value in Health 2018 21 Suppl 3 S300 1 10.1016\/j.jval.2018.09.1790","DOI":"10.1016\/j.jval.2018.09.1790"},{"issue":"7","key":"10.1002\/14651858.CD014574.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13696998.2019.1592180","article-title":"Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England","volume":"22","author":"Harris","year":"2019","journal-title":"Journal of Medical Economics"},{"issue":"10","key":"10.1002\/14651858.CD014574.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Grillo-L\u00f3pez","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD014574.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD014574.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/wnl.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0022|cit22","unstructured":"Tandan R Potter C Bradshaw DY Pilot trial of rituximab in myasthenia gravis Neurology 2008 70 Suppl 1 A301"},{"issue":"5","key":"10.1002\/14651858.CD014574.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD014574.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"Doc12","DOI":"10.3205\/000239","article-title":"Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab","volume":"14","author":"Sudulagunta","year":"2016","journal-title":"German Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD014574.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Practical Neurology"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202.","article-title":"PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents","volume":"6","author":"Kanth","year":"2016","journal-title":"Neurology. Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD014574.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinaemia, late-onset neutropenia, and infections folloiwng rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0032|cit32","unstructured":"UK Health Security Agency Department of Health & Social Care Immunisation Against Infectious Disease; 2021 www.gov.uk\/government\/collections\/immunisation-against-infectious-disease-the-green-book#the-green-book"},{"issue":"7","key":"10.1002\/14651858.CD014574.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3899\/jrheum.180784","article-title":"Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: executive summary","volume":"46","author":"Papp","year":"2019","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD014574.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0035|cit35","unstructured":"European Medicines Agency Annex I Summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0038|cit38","unstructured":"NHS England Clinical Commissioning Policy Statement: Rituximab bio-similar for the treatment of myasthenia gravis (adults). NHS England Reference:170084P Version 2 https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/04\/Rituximab-biosimilar-for-the-treatment-of-myasthenia-gravis-adults-v2.pdf"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0039|cit39","unstructured":"Nawrat A Why are patients struggling to access life-saving immune globulin?; 24 February 2020 Available at https:\/\/www.pharmaceutical-technology.com\/features\/immune-globulin-shortages\/"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0040|cit40","unstructured":"Highlights of prescribing information; revised April 2022 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0041|cit41","unstructured":"FDA approves new treatment for myasthenia gravis; 17 December 2021 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"ImmunoTargets and Therapy"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0043|cit43","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Flemyng E Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version February 2022 Available at https:\/\/community.cochrane.org\/sites\/default\/files\/uploads\/MECIR%20Version%20February%202022.pdf"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014574","article-title":"Rituximab for myasthenia gravis","author":"Dodd","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Barohn","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"10.1002\/14651858.CD014574.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rutiximab in MuSK myasthenia","volume":"78","author":"Diaz-Maera","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD014574.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1002\/14651858.CD014574.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1002\/14651858.CD014574.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle & Nerve"},{"issue":"18","key":"10.1002\/14651858.CD014574.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable tool for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL 15 for following health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0054|cit54","unstructured":"Covidence Veritas Health Innovation 2022"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0056|cit56","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0057|cit57","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor (s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0058|cit58","unstructured":"ORBIT classifications (benefit outcomes) https:\/\/outcome-reporting-bias.org\/BenefitOutcomes"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0059|cit59","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD014574.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0061|cit61","unstructured":"GRADEpro GDT McMaster University and Evidence Prime 2024"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0062|cit62","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0063|cit63","unstructured":"Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with myasthenia gravis: clinical trial to evaluate the efficacy and safety of ritxuximab in generalized achr-antibody positive myasthenia gravis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-005619-35-IT"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0064|cit64","unstructured":"Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) clinicaltrials.gov\/study\/NCT05868837"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0065|cit65","unstructured":"Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia: a PROBE multicenter open-label randomized controlled trial www.clinicaltrials.gov\/study\/NCT06342544"},{"issue":"11","key":"10.1002\/14651858.CD014574.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0067|cit67","unstructured":"A study evaluating the safety and efficacy of rituximab in patients with myasthenia gravis https:\/\/clinicaltrials.gov\/study\/NCT02950155"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0068|cit68","unstructured":"A clinical trial investigating the effect and safety of the drug rituximab in patients with new onset myasthenia gravis, an autoimmune condition affecting muscle strength https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005749-30\/SE https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005749-30\/results"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD014574.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1002\/ana.24498","article-title":"M743 Phase 2 trial of rituximab in myasthenia gravis: study update","volume":"78","author":"Nowak","year":"2015","journal-title":"Annals of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014574.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.3233\/JND-160001","article-title":"LB 1.1\/#378 A phase 2 trial of rituximab in myasthenia gravis: study update","volume":"3","author":"Nowak","year":"2016","journal-title":"Journal of Neuromuscular Disease"},{"issue":"17 Suppl 1","key":"10.1002\/14651858.CD014574.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"P4","DOI":"10.1212\/WNL.0000000000205956","article-title":"Trial design and impact on study outcome: post-hoc analysis of the BeatMG study based on RINOMAX trial criteria","volume":"102","author":"Roy","year":"2024","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014574.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"e2192-3","DOI":"10.3233\/JND-189001","article-title":"#967 B-cell targeted treatment in myasthenia gravis (BeatMG): a phase 2 trial of rituximab in myasthenia gravis: topline results","volume":"5","author":"Nowak","year":"2018","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0074|cit74","unstructured":"BeatMG: phase II trial of rituximab in myasthenia gravis https:\/\/clinicaltrials.gov\/study\/NCT02110706"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014574.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1002\/mus.26647","article-title":"Rituximab in patients with moderate to severe myasthenia gravis: a subgroup analysis of the BeatMG study","volume":"60","author":"Nowak","year":"2019","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD014574.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta\u2011analysis","volume":"38","author":"Ma","year":"2024","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1002\/14651858.CD014574.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacca","year":"2023","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"725700","DOI":"10.3389\/fneur.2021.725700","article-title":"Efficacy and safety of immunotherapies in refractory myasthenia gravis: a systematic review and meta-analysis","volume":"12","author":"Feng","year":"2021","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhoa","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD014574.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"Journal of Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD014574.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"Journal of Clinical Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD014574.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev","year":"2017","journal-title":"Neuromuscular Disorders"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:01:25Z","timestamp":1787745685000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014574.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":83,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014574.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]}}}